Clinical Trials Logo
  1. Home
  2. Placenta Previa
  3. NCT03772184
  4. Details
NCT03772184 Clinical Trial

Modified Cervical Inversion During CS in Placenta Previa

Placenta Previa Clinical Trial

Official title:
Alalfy Modofied Cervical Inversion During CS in Placenta Previa

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03772184
Other study ID # Modified cervical inversion
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 10, 2019
Est. completion date May 15, 2019

Study information
Verified date February 2022
Source Aljazeera Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

There is an increasing rates of placenta previa nowadays

Description:

several techniques were described to control bleeding .

Recruitment information / eligibility
Status Completed
Enrollment 240
Est. completion date May 15, 2019
Est. primary completion date May 12, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 22 Years to 40 Years
Eligibility Inclusion Criteria: - pregnant women 38 weeks or more with placenta previa Exclusion Criteria: - pregnant ladies with normally implanted placenta or placenta accreat , increta or percreta

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• Cervical inversion
inverting the cervical lip after delivery

Locations
Country Name City State
Egypt Algazeerah and helwan university Giza

Sponsors (2)
Lead Sponsor Collaborator
Aljazeera Hospital Suez Canal University

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary The number of women whose placental bed bleeding will be controlled by cervical inversion cervical inversion how can the cervical inversion technique controls the placental bed bleeding within an hour
See also
  Status Clinical Trial Phase
Recruiting NCT04518163 - Bakri Balloon Plus Tranexamic Acid During Cesarean Delivery for Placenta Previa N/A
Recruiting NCT04518150 - Combined Bilateral Uterine Artery Ligation and Bakri Balloon During Cesarean Section N/A
Recruiting NCT03638024 - Cell-free Fetal DNA Concentration in Cases of Abnormal Placental Invasion .
Terminated NCT01996345 - Vaginal Pessary Versus Expectant Management for Placenta Previa N/A
Recruiting NCT04609527 - Management of Placenta Accreta Spectrum Phase 2/Phase 3
Completed NCT03321435 - The Placenta Previa and Fetal Weight N/A
Completed NCT03431116 - Low Implanted Second Trimester Placenta and Placenta Previa N/A
Enrolling by invitation NCT05529381 - Anxiety and Depressive Symptoms in Placenta Previa / Accreta
Completed NCT04264234 - Management Of Placenta Previa Cases And Determination Of Hospitalization Criteria N/A
Completed NCT05340205 - Blood Loss During Cesarean Delivery in Placenta Previa Patients Phase 4
Completed NCT03570723 - Glove-loaded Foley's Catheter Tamponade for Cesarean Section for Placenta Previa N/A
Completed NCT05283122 - Mostafa Maged Technique to Control and Prevent the Post-Partum Bleeding From the Lower Uterine Segment in Placenta Previa Cases N/A
Withdrawn NCT01442207 - Cerclage for Prevention on Preterm Birth in Women With Placenta Previa Phase 3
Not yet recruiting NCT03451136 - Cervical Length in Cases of Placenta Previa N/A
Completed NCT02966197 - Efficacy of Prophylactic Internal Iliac Artery Balloon Catheterization in the Management of Placenta Previa and Accreta N/A
Recruiting NCT02590484 - The Cervix as a Natural Tamponade in Postpartum Hemorrhage Caused by Placenta Previa and Placenta Previa Accreta N/A
Recruiting NCT05802251 - Sonographic Parameters and Risk of Antepartum Hemorrhage in Asymptomatic Women With Placenta Previa: A Cohort Study
Completed NCT03542552 - Nifedipine Versus Magnesium Sulfate for Prevention of Preterm Labor in Symptomatic Placenta Previa Phase 3
Recruiting NCT03124472 - Effect of Uterine Artery Ligation Prior to Uterine Incision in Women With Placenta Previa N/A
Recruiting NCT03633175 - Progesterone in Patients With Placenta Previa Phase 2